Nutritional and metabolic factors in amyotrophic lateral sclerosis

A Ludolph, L Dupuis, E Kasarskis, F Steyn… - Nature Reviews …, 2023 - nature.com
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease that is
classically thought to impact the motor system. Over the past 20 years, research has started …

Recent updates on the genetics of amyotrophic lateral sclerosis and frontotemporal dementia

L Kirola, A Mukherjee, M Mutsuddi - Molecular Neurobiology, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) primarily affect the
motor and frontotemporal areas of the brain, respectively. These disorders share clinical …

[HTML][HTML] Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

TM Miller, ME Cudkowicz, A Genge… - … England Journal of …, 2022 - Mass Medical Soc
Background The intrathecally administered antisense oligonucleotide tofersen reduces
synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with …

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

T Miller, M Cudkowicz, PJ Shaw… - … England Journal of …, 2020 - Mass Medical Soc
Background Tofersen is an antisense oligonucleotide that mediates the degradation of
superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis …

Genetic variability in sporadic amyotrophic lateral sclerosis

SH Van Daele, M Moisse, JJFA van Vugt… - Brain, 2023 - academic.oup.com
With the advent of gene therapies for amyotrophic lateral sclerosis (ALS), there is a surge in
gene testing for this disease. Although there is ample experience with gene testing for …

Value of systematic genetic screening of patients with amyotrophic lateral sclerosis

SR Shepheard, MD Parker, J Cooper-Knock… - Journal of Neurology …, 2021 - jnnp.bmj.com
Objective The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis
(ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of 44 …

[HTML][HTML] Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting–a 12-month multicenter cohort study from the German early access program

M Wiesenfarth, J Dorst, D Brenner, Z Elmas… - …, 2024 - thelancet.com
Summary Background In April 2023, the antisense oligonucleotide tofersen was approved
by the US Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral …

Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: treatment experience in clinical practice

T Meyer, P Schumann, P Weydt, S Petri, Y Koc… - Muscle & …, 2023 - Wiley Online Library
Abstract Introduction/Aims In amyotrophic lateral sclerosis (ALS) caused by superoxide
dismutase 1 (SOD1) gene mutations (SOD1‐ALS), the antisense oligonucleotide tofersen …

Genetics of amyotrophic lateral sclerosis

JM Gregory, D Fagegaltier, H Phatnani… - Current Genetic Medicine …, 2020 - Springer
Abstract Purpose of Review Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-
FTD) spectrum disorder is a rare fatal disease with strong genetic influences. The …

Expanding the stdpopsim species catalog, and lessons learned for realistic genome simulations

ME Lauterbur, MIA Cavassim, AL Gladstein, G Gower… - Elife, 2023 - elifesciences.org
Simulation is a key tool in population genetics for both methods development and empirical
research, but producing simulations that recapitulate the main features of genomic datasets …